MARKET

MRUS

MRUS

Merus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.80
+0.58
+3.58%
After Hours: 16.80 0 0.00% 16:00 05/20 EDT
OPEN
16.39
PREV CLOSE
16.22
HIGH
17.25
LOW
15.91
VOLUME
262.02K
TURNOVER
0
52 WEEK HIGH
33.09
52 WEEK LOW
14.78
MARKET CAP
731.64M
P/E (TTM)
-8.9276
1D
5D
1M
3M
1Y
5Y
Merus a positive Catalyst Watch at Citi ahead of ASCO presentation
Citi, which has a buy rating on Merus (NASDAQ:MRUS), is adding the biotech to its Catalyst Watch list ahead of presenting updated early-stage data on zenocutuzumab at the American Society
Seekingalpha · 3d ago
Citigroup Trims Merus' Price Target to $37 From $38, Maintains Buy Rating
MT Newswires · 3d ago
Merus to Present at the H.C. Wainwright Global Investment Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill...
GlobeNewswire · 5d ago
Party Time: Brokers Just Made Major Increases To Their Merus N.V. (NASDAQ:MRUS) Earnings Forecasts
Merus N.V. ( NASDAQ:MRUS ) shareholders will have a reason to smile today, with the analysts making substantial...
Simply Wall St. · 05/14 12:00
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of 34.85% and 36.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 22:35
Merus Q1 EPS $(0.43) Down From $(0.28) YoY, Sales $11.65M Up From $8.35M YoY
Merus (NASDAQ:MRUS) reported quarterly losses of $(0.43) per share. This is a 53.57 percent decrease over losses of $(0.28) per share from the same period last year. The company reported $11.65 million in sales this
Benzinga · 05/09 21:14
BRIEF-Merus Announces Financial Results For The First Quarter 2022 And Provides Business Update
reuters.com · 05/09 21:12
Merus GAAP EPS of -$0.43 beats by $0.22, revenue of $11.66M beats by $2.29M
Merus press release (NASDAQ:MRUS): Q1 GAAP EPS of -$0.43 beats by $0.22. Revenue of $11.66M (+39.6% Y/Y) beats by $2.29M.
Seekingalpha · 05/09 20:55
More
No Data
Learn about the latest financial forecast of MRUS. Analyze the recent business situations of Merus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

60.00%Strong Buy
40.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MRUS stock price target is 41.44 with a high estimate of 45.00 and a low estimate of 33.00.
High45.00
Average41.44
Low33.00
Current 16.80
EPS
Actual
Estimate
-0.57-0.43-0.28-0.14
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 108
Institutional Holdings: 36.80M
% Owned: 84.50%
Shares Outstanding: 43.55M
TypeInstitutionsShares
Increased
44
1.67M
New
10
1.05M
Decreased
23
1.30M
Sold Out
17
1.16M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
Anand Mehra
President/Chief Executive Officer/Chief Financial Officer/Executive Director
Sven Lundberg
Non-Executive Vice Chairman/Non-Executive Director
Gregory Perry
Chief Technology Officer
Cornelis Adriaan de Kruif
General Counsel
Peter Silverman
Other
Alexander Bakker
Other
Andrew Joe
Other
Hui Liu
Non-Executive Independent Director
Mark Iwicki
Non-Executive Independent Director
Leonard Kanavy
Non-Executive Independent Director
Paolo Pucci
Non-Executive Independent Director
Victor Sandor
No Data
No Data
About MRUS
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Webull offers kinds of Merus NV stock information, including NASDAQ:MRUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRUS stock methods without spending real money on the virtual paper trading platform.